anticonvulsant agent 1

Anticonvulsant agent 1 is a chemical compound with potent anticonvulsant properties.

5-[(1S,2S)-2-[(Cyclopropylmethyl)amino]cyclopropyl]-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide hydrochloride is a cyclopropanoid enzyme compound that acts as a lysine-specific demethylase-1 inhibitor for schizophrenia, developmental disorders, and neurodegenerative diseases.

Anticonvulsant agent 10 (Compound 6d) is an inhibitor targeting the Keap1-Nrf2 interaction, with a strong activity showing an ED50 of 0.04 mmol/kg. By inhibiting the Keap1-Nrf2 binding, it activates the Nrf2/ARE pathway, providing anticonvulsant and neuroprotective effects, making it useful for research in epilepsy and neuroprotection.

GABAA receptor agent 1 has strong anticonvulsant activity and is a high affinity ligand of GABAA receptor.

Methsuximide is a succinimide anticonvulsant medication marketed as a racemate under the tradenames Petinutin and Celontin. Methsuximide its therapeutic efficacy is largely attributed to its active metabolite N-desmethylmethosuximide, which has a longer half-life and achieves higher plasma concentrations, making it central to the studies of epilepsy pharmacotherapy and metabolite-driven drug action.

3-Methyl-GABA, an anticonvulsant agent [1] [2], acts as a potent activator of GABA aminotransferase, fits the binding pocket of the GABA A receptor (GABAaR), and activates L-glutamic acid decarboxylase (GAD).

Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide (T0267) is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide (T0267) inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (T0267) (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid or dihydroxyphenyl acetic acid , and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.

Lamotrigine hydrate is an effective oral active anticonvulsant or antiepileptic agent that selectively blocks voltage-gated Na + channels, stabilizes presynaptic neuronal membranes and inhibits glutamate release. Lamotrigine hydrate can be used in epilepsy, focal seizure, et al [1] [2].

GABAA receptor agent 8 (compound 5e) is a potent positive modulator of the GABAA receptor, exhibiting anticonvulsant activity in both in vitro and in vivo studies, with low neurotoxicity, indicating its potential in epilepsy research [1].

GABAA receptor agent 7 (compound 5c) is a potent positive modulator of the GABAA receptor with anticonvulsant activity in vitro and in vivo, and low neurotoxicity, making it suitable for epilepsy research [1].

Anticonvulsant agent 3, a 2-amino derivative, exhibits anticonvulsant activity [1].

Ethotoin (Peganone), an orally active anticonvulsant agent utilized in epilepsy research, is a hydantoin derivative analogous to phenytoin [1].

Methsuximide (Standard) is a reference standard for research and analysis in studies involving Methsuximide. Methsuximide is an anticonvulsant agent which appeared to be effective in petit mal, psychomotor and focal motor attacks [1].

VH-N412 is a carrier-modified neurotrophin (NT) known for its excellent ability to penetrate the blood-brain barrier. This compound actively binds to both low-density lipoprotein receptor (LDLR) and neurotropin receptor 1 (NTSR-1), acting as an inducer of pharmacologically induced hypothermia (PIH). Additionally, VH-N412 exhibits anticonvulsant and neuroprotective properties, making it a valuable agent for research in neurological disorders such as epilepsy.